Morgans Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Price Target Raised 5.5% to A$43.60/Share by Morgans
ResMed Cut to Mkt Weight From Overweight by Wilsons >RMD.AU
ResMed Is Maintained at Neutral by Piper Sandler
ResMed Price Target Raised 2.1% to A$44.80/Share by Barrenjoey
ResMed Price Target Raised 3% to A$238.00/Share by RBC Capital Markets
J.P. Morgan Remains a Buy on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
UBS Keeps Their Hold Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
Citi Keeps Their Hold Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Initiated at Buy by Goldman Sachs
ResMed Initiated at Hold by Stifel
ResMed Price Target Announced at $250.00/Share by Stifel
J.P. Morgan Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Is Maintained at Outperform by Baird
ResMed Price Target Raised 4.3% to A$37.80/Share by Macquarie
ResMed Is Maintained at Buy by B of A Securities
ResMed Initiated at Outperform by Baird
ResMed Price Target Announced at $180.00/Share by Wolfe Research
ResMed Cut to Underperform From Peer Perform by Wolfe Research
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD) and Bayer (GB:0P6S)